Pozen drops one migraine drug, to pursue another (Reuters)
Reuters - Pozen Inc. said on Friday it would
no longer pursue U.S. approval of its experimental migraine
drug MT 100, one day after a U.S. advisory panel said another
clinical trial was needed.
Stumble It!
Tweet This
Bookmark on Delicious
Share on Facebook
Share on MySpace